Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesSleep MedicineSummaCare Hypoglossal Prior Auth Update | OpenPaye…
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for FDA-approved hypoglossal nerve stimulation systems used to treat moderate to severe obstructive sleep apnea in SummaCare commercial and Medicare members.

    Policy Summary
    PayerSummaCare
    PolicyHypoglossal Nerve Stimulation for Obstructive Sleep Apnea
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewAug 6, 2026
    Next Review DateN/A
    Key ActionDocument CPAP failure or intolerance before requesting authorization for hypoglossal nerve stimulation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Commercial minimum age
    22+Medicare minimum age
    <35BMI requirement
    15 to <100/hrCommercial AHI range

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    15–65/hr
    Medicare AHI range
    24 monthsPSG recency

    Medical Necessity and Coverage Criteria

    Commercial Member Criteria

    For commercial members, an FDA-approved hypoglossal nerve neurostimulation system is medically necessary for moderate to severe obstructive sleep apnea only when ALL of the following criteria are met.

    ALL of the following

    • Member is 18 years of age or older.
    • Body mass index (BMI) is less than 35 kg/m².< 35 kg/m²
    • Polysomnography (PSG) was performed within 24 months before the first consultation for hypoglossal nerve stimulation (HGNS) implant.
    • Member has predominantly obstructive events, defined as central and mixed apneas comprising less than 25% of the total apnea-hypopnea index (AHI).< 25% central and mixed apneas
    • AHI is at least 15 and less than 100 events per hour.15 to < 100 events/hour
    • At least one month of CPAP monitoring documentation demonstrates CPAP failure or CPAP intolerance.
    • CPAP failure is defined as an AHI greater than 15 despite CPAP use; CPAP intolerance is defined as CPAP use for less than 4 hours per night on 5 nights per week.< 4 hours/night on 5 nights/week for intolerance
    • Drug-induced sleep endoscopy (DISE) demonstrates absence of complete concentric collapse at the soft-palate level.
    • There is no anatomical finding that would compromise the performance of upper-airway stimulation.

    Medicare Member Criteria

    For Medicare beneficiaries, FDA-approved hypoglossal nerve neurostimulation is medically reasonable and necessary for moderate to severe obstructive sleep apnea only when ALL of the following criteria are met.

    ALL of the following

    • Beneficiary is 22 years of age or older.
    • Body mass index (BMI) is less than 35 kg/m².< 35 kg/m²
    • Polysomnography (PSG) was performed within 24 months before the first consultation for HGNS implant.
    • Beneficiary has predominantly obstructive events, defined as central and mixed apneas comprising less than 25% of the total AHI.< 25% central and mixed apneas

    Hypoglossal nerve neurostimulation is not medically reasonable and necessary, and is considered experimental and investigational, for all indications other than the covered treatment of moderate to severe adult obstructive sleep apnea. Non-FDA-approved hypoglossal nerve neurostimulation is likewise not medically reasonable and necessary and is considered experimental and investigational for adult obstructive sleep apnea.

    The contraindications and exclusion conditions described below preclude coverage. They include central or mixed apneas exceeding one-quarter of the total AHI, BMI of 35 kg/m² or greater, potentially interacting implantable devices, and the other clinical, anatomical, functional, MRI-related, and device-operation conditions listed in the Contraindications block.

    Because of documented inconsistency in determining complete concentric collapse, the inserting provider must be certified through the FDA-approved manufacturer's second-opinion validation service by submitting video clips demonstrating at least 80% agreement across at least 15 consecutive studies. The provider must retain documentation and submit it to the contractor when requested.

    HGNS is not medically reasonable and necessary for all other indications or when a non-FDA-approved device is used. Coverage is limited to the FDA-approved system and the covered obstructive sleep apnea indications and criteria specified above.

    Central or mixed apneas comprising more than 25% of the total AHI are a noncoverage condition. Any contraindication listed for HGNS—including an interacting implantable device, BMI of 35 kg/m² or greater, or another condition that prevents safe or effective use—also makes the service not medically reasonable and necessary.

    Codes and Key Thresholds

    Covered CPT CodesCPTCovered
    64568Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator
    64582insertion of hypoglossal nerve neurostimulator electrode, generator and breathing sensor electrode
    64583revision or replacement of hypoglossal nerve neurostimulator electrode and breathing sensor electrode with connection to existing generator
    64854removal of hypoglossal nerve neurostimulator electrode and generator and breathing sensor electrode
    Commercial minimum age
    Minimum age18 years or older for commercial members
    Medicare minimum age
    Minimum age22 years or older for Medicare beneficiaries
    BMI
    BMI requirementLess than 35 kg/m²
    PSG recency
    PSG timing

    Authorization and Documentation Requirements

    Prior Authorization

    Commercial HGNS Prior Authorization

    Commercial members require prior authorization before implantation of an FDA-approved hypoglossal nerve stimulation (HGNS) system. Submit documentation that all applicable medical-necessity criteria are met.

    • Applies to commercial members; self-funded commercial groups should be checked against the applicable plan document.
    Prior Authorization

    Medicare HGNS Authorization

    For Medicare beneficiaries, submit the documentation required under CMS guidance and the applicable local coverage determination (LCD) criteria for FDA-approved HGNS. Medicare coverage requires all applicable covered-indication criteria to be satisfied.

    • Medicare covered range: AHI 15–65 events per hour.
    • Beneficiary must be at least 22 years old and have BMI less than 35 kg/m².

    Clinical Background

    Obstructive sleep apnea is characterized by recurrent obstruction of the upper airway during sleep. It is associated with conditions including hypertension, cardiovascular disease, arrhythmia, cerebrovascular disease, daytime sleepiness, and mood disorders.

    Hypoglossal nerve stimulation uses an implanted pulse generator, a respiratory-sensing lead, and a stimulating lead attached to the hypoglossal nerve. The system synchronizes tongue stimulation with the patient's breathing to help maintain airway patency and provides an alternative for appropriately selected adults who cannot adequately use CPAP.

    Policy Definitions

    Predominantly obstructive events
    DefinitionCentral and mixed apneas comprise less than 25% of the total apnea-hypopnea index (AHI), indicating predominantly obstructive events
    CPAP failure
    DefinitionAHI greater than 15 despite CPAP usage
    CPAP intolerance
    CPAP useLess than 4 hours per night on 5 nights per week
    Medicare criterionMedicare also recognizes that the CPAP device has been returned
    Policy Summary
    PayerSummaCare
    PolicyHypoglossal Nerve Stimulation for Obstructive Sleep Apnea
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewAug 6, 2026
    Next Review DateN/A
    Key ActionDocument CPAP failure or intolerance before requesting authorization for hypoglossal nerve stimulation.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCodes and Key ThresholdsAuthorization and Documentation RequirementsClinical BackgroundPolicy Definitions
    AHI is 15 to 65 events per hour.15–65 events/hour
  1. Documentation demonstrates CPAP failure or CPAP intolerance, including shared decision-making between the attending provider and the patient after consultation with a sleep expert.
  2. CPAP failure is defined as an AHI greater than 15 despite CPAP use; CPAP intolerance is defined as CPAP use for less than 4 hours per night on 5 nights per week or return of the CPAP device.
  3. Drug-induced sleep endoscopy (DISE) demonstrates absence of complete concentric collapse at the soft-palate level.
  4. There is no other anatomical finding that would compromise device performance, including tonsil size 3 or 4 according to a standardized tonsillar hypertrophy grading scale.
  5. Performed within 24 months of the first consultation for HGNS implant
    Commercial AHI
    Qualifying AHI15 and less than 100 events per hour
    Medicare AHI
    Qualifying AHI15 to 65 events per hour
    Central and mixed apneas
    Maximum proportionCentral and mixed apneas must comprise less than 25% of total AHI
    Commercial CPAP monitoring
    Monitoring periodMinimum of 1 month of CPAP monitoring documentation
    CPAP intolerance
    Usage thresholdCPAP use for less than 4 hours per night on 5 nights per week
    DISE provider validation
    Validation requirementAt least 80% agreement in at least 15 consecutive studies through the FDA-approved manufacturer's second-opinion service
    Documentation Required

    Document CPAP Failure or Intolerance

    Document that the member or beneficiary has failed or cannot tolerate CPAP before requesting HGNS authorization. The record must support the applicable commercial or Medicare definition and, for Medicare, include shared decision making after consultation with a sleep expert.

    • CPAP failure: AHI greater than 15 despite CPAP use.
    • CPAP intolerance: use of CPAP less than 4 hours per night on 5 nights per week; Medicare also recognizes return of the CPAP device.
    Documentation Required

    Submit a Recent Qualifying Sleep Study

    Submit a qualifying polysomnography (PSG) performed within 24 months before the first HGNS implant consultation. The sleep study must report the AHI and demonstrate predominantly obstructive events, with central and mixed apneas comprising less than 25% of the total AHI.

    • Commercial AHI requirement: 15 and less than 100 events per hour.
    • Medicare AHI requirement: 15–65 events per hour.
    • Include central and mixed apnea details in the submitted PSG report.
    Documentation Required

    Document CPAP Treatment History

    Provide treatment-history records showing that the applicable CPAP requirement has been met. Commercial authorization requires at least one month of CPAP monitoring documentation; Medicare requires documentation of CPAP failure or intolerance and shared decision making regarding CPAP intolerance after sleep-expert consultation.

    • Commercial: document at least one month of monitoring, with AHI greater than 15 despite use or use below 4 hours per night on 5 nights per week.
    • Medicare: document AHI greater than 15 despite CPAP, use below 4 hours per night on 5 nights per week, or return of the CPAP device.
    Documentation Required

    Provide DISE and Airway Findings

    Submit drug-induced sleep endoscopy (DISE) findings confirming absence of complete concentric collapse at the soft-palate level and documenting that no anatomical finding would compromise upper-airway stimulation.

    • Include relevant anatomy, such as tonsil findings; Medicare identifies tonsil size 3 or 4 as an example of anatomy that may compromise device performance.
    Documentation Required

    Validate Provider DISE Qualification

    Retain manufacturer validation documentation for the inserting provider. Because of documented inconsistency in identifying complete concentric collapse, the provider must be certified through the FDA-approved manufacturer’s second-opinion validation service.

    • Validation requires video-clip submissions demonstrating at least 80% agreement across at least 15 consecutive studies.
    • Provide the documentation to the contractor if requested.
    Documentation Required

    Document Medicare Shared Decision Making

    For Medicare cases, retain documentation of shared decision making between the attending provider and the patient regarding CPAP intolerance and HGNS. The discussion must be documented as a provider-patient conversation, not merely a discussion among providers.

    • The record should include the patient discussion after consultation with a sleep expert.
    • Provide the documentation to the contractor if requested.
    Denial Risk

    Noncovered Indication or Device

    Expect denial when HGNS is requested for an indication other than the covered treatment of moderate-to-severe obstructive sleep apnea, when the system is not FDA approved, or when central and mixed apneas exceed one-quarter of the total AHI.

    • Other indications are not medically reasonable and necessary under CMS limitations.
    • Non-FDA-approved HGNS systems are not medically reasonable and necessary for adult obstructive sleep apnea.
    • Central and mixed apneas greater than 25% of total AHI are a contraindication.
    Denial Risk

    Screen for Contraindications

    Screen for and document the absence of all applicable contraindications before authorization. Any listed contraindication may result in denial, including BMI at or above 35 kg/m², interacting implanted devices, or conditions that impair airway control, pulmonary or cardiac status, sleep assessment, device operation, or MRI compatibility.

    • Neuromuscular disease; hypoglossal-nerve palsy; compromised neurological control of the upper airway; or an implanted device that could unintentionally interact with HGNS.
    • Severe restrictive or obstructive pulmonary disease; moderate-to-severe pulmonary arterial hypertension; severe valvular heart disease; NYHA class III or IV heart failure; myocardial infarction or severe cardiac arrhythmias within 6 months; or persistent uncontrolled hypertension despite medication.
    • Active serious mental illness interfering with activities of daily living or operation of HNS; coexisting non-respiratory sleep disorders that confound assessment; inability to operate the sleep remote or lack of necessary assistance; or current/planned pregnancy.
    • MRI incompatibility or inability to meet manufacturer conditions: beneficiaries requiring MRI with model 3024 are contraindicated; model 3028 MRI is limited to the head and extremities when manufacturer conditions and precautions are met.
    Documentation Required

    Confirm All Medical-Necessity Criteria

    Authorization requires every applicable clinical and documentation criterion to be satisfied. Confirm age, BMI, qualifying PSG and AHI, predominantly obstructive events, CPAP failure or intolerance, DISE findings, and absence of compromising anatomy before submission.

    • Commercial members: age 18 or older, BMI less than 35 kg/m², PSG AHI 15 to less than 100 events per hour, and at least one month of CPAP monitoring.
    • Medicare beneficiaries: age 22 or older, BMI less than 35 kg/m², PSG AHI 15–65 events per hour, and Medicare-specific CPAP and shared-decision requirements.
    Denial Risk

    DISE Validation Must Be Documented

    Authorization is at risk when manufacturer DISE validation is not documented. Retain evidence that the inserting provider completed the required second-opinion validation process and can produce it upon request.

    • Document at least 80% agreement in at least 15 consecutive studies through the manufacturer’s validation service.
    Denial Risk

    Document Shared Decision Making

    Medicare coverage is at risk when the required provider-patient shared decision-making conversation is not documented. Retain the attending provider’s record of discussing CPAP intolerance and HGNS with the patient.

    • Documentation must reflect a conversation between the attending provider and patient, not between multiple providers.
    Hypoglossal nerve stimulation system
    Pulse generatorImplanted pulse generator
    Sensing leadRespiratory or breathing-sensing lead
    Stimulating leadStimulating lead surgically placed on the hypoglossal nerve